ORGN001 (formerly ALXN1101)

DRUG2 trials

Sponsors

Origin Biosciences

Conditions

Molybdenum Cofactor Deficiency, Type A

Phase 2

Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP

CompletedNCT02047461

Origin BiosciencesMolybdenum Cofactor Deficiency, Type A

Start: 2014-04-30End: 2022-10-31Updated: 2023-10-17

Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

CompletedNCT02629393

Origin BiosciencesMolybdenum Cofactor Deficiency, Type A

Start: 2016-05-31End: 2022-10-31Updated: 2023-10-17